Diane Goéré

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/625107/publications.pdf

Version: 2024-02-01

186 papers 9,633 citations

51 h-index 91 g-index

191 all docs

191 docs citations

191 times ranked

8351 citing authors

#	Article	IF	CITATIONS
1	Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin. Journal of Clinical Oncology, 2009, 27, 681-685.	1.6	758
2	Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 256-266.	10.7	405
3	Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer. Clinical Cancer Research, 2012, 18, 5314-5328.	7. O	311
4	Are G3 ENETS neuroendocrine neoplasms heterogeneous?. Endocrine-Related Cancer, 2013, 20, 649-657.	3.1	275
5	A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 Journal of Clinical Oncology, 2018, 36, LBA3503-LBA3503.	1.6	241
6	Is There a Possibility of a Cure in Patients With Colorectal Peritoneal Carcinomatosis Amenable to Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy?. Annals of Surgery, 2013, 257, 1065-1071.	4.2	219
7	Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. Journal of Clinical Oncology, 2019, 37, 2028-2040.	1.6	218
8	Results of Systematic Second-look Surgery Plus HIPEC in Asymptomatic Patients Presenting a High Risk of Developing Colorectal Peritoneal Carcinomatosis. Annals of Surgery, 2011, 254, 289-293.	4.2	206
9	Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdominal Imaging, 2008, 33, 87-93.	2.0	182
10	The Impact of Perioperative Chemotherapy on Survival in Patients With Gastric Signet Ring Cell Adenocarcinoma. Annals of Surgery, 2011, 254, 684-693.	4.2	177
11	Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study. Annals of Surgical Oncology, 2015, 22, 2958-2964.	1.5	177
12	Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure. Annals of Surgical Oncology, 2008, 15, 219-226.	1.5	168
13	Utility of staging laparoscopy in subsets of biliary cancers. Surgical Endoscopy and Other Interventional Techniques, 2006, 20, 721-725.	2.4	164
14	Hepatic Metastases From Neuroendocrine Tumors With a "Thin Slice―Pathological Examination. Annals of Surgery, 2010, 251, 307-310.	4.2	164
15	Results of Two Bi-Institutional Prospective Studies Using Intraperitoneal Oxaliplatin With or Without Irinotecan During HIPEC After Cytoreductive Surgery for Colorectal Carcinomatosis. Annals of Surgery, 2011, 254, 294-301.	4.2	150
16	Definition of Patients Presenting a High Risk of Developing Peritoneal Carcinomatosis After Curative Surgery for Colorectal Cancer: A Systematic Review. Annals of Surgical Oncology, 2013, 20, 183-192.	1.5	144
17	Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study. Lancet Oncology, The, 2020, 21, 1147-1154.	10.7	143
18	A Comparative Study of Complete Cytoreductive Surgery Plus Intraperitoneal Chemotherapy to Treat Peritoneal Dissemination From Colon, Rectum, Small Bowel, and Nonpseudomyxoma Appendix. Annals of Surgery, 2010, 251, 896-901.	4.2	141

#	Article	IF	CITATIONS
19	Results of Systematic Second-Look Surgery in Patients at High Risk of Developing Colorectal Peritoneal Carcinomatosis. Annals of Surgery, 2008, 247, 445-450.	4.2	136
20	Optimization of Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin Plus Irinotecan at 43°C After Compete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients. Annals of Surgical Oncology, 2007, 14, 1818-1824.	1.5	131
21	Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?. European Journal of Endocrinology, 2010, 162, 1147-1153.	3.7	126
22	Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin. Annals of Surgical Oncology, 2007, 14, 3188-3194.	1.5	125
23	Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. European Journal of Surgical Oncology, 2021, 47, 11-35.	1.0	120
24	Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer. Annals of Surgical Oncology, 2016, 23, 114-119.	1.5	118
25	Prolonged Survival of Initially Unresectable Hepatic Colorectal Cancer Patients Treated With Hepatic Arterial Infusion of Oxaliplatin Followed by Radical Surgery of Metastases. Annals of Surgery, 2010, 251, 686-691.	4.2	116
26	Predictive Factors for Hypertrophy of the Future Remnant Liver After Selective Portal Vein Embolization. Annals of Surgical Oncology, 2010, 17, 2081-2089.	1.5	114
27	Chemotherapy Does Not Impair Hypertrophy of the Left Liver After Right Portal Vein Obstruction. Journal of Gastrointestinal Surgery, 2006, 10, 365-370.	1.7	111
28	Pancreaticoduodenectomy with Mesentericoportal Vein Resection for Adenocarcinoma of the Pancreatic Head. World Journal of Surgery, 2006, 30, 1526-1535.	1.6	110
29	Hemorrhage after pancreaticoduodenectomy: when is surgery still indicated?. American Journal of Surgery, 2007, 194, 3-9.	1.8	108
30	Peritoneal carcinomatosis of colorectal origin. Gastroenterologie Clinique Et Biologique, 2006, 30, 1200-1204.	0.9	95
31	Should Patients With Peritoneal Carcinomatosis of Colorectal Origin With Synchronous Liver Metastases Be Treated With a Curative Intent? A Case-Control Study. Annals of Surgery, 2013, 258, 116-121.	4.2	92
32	Transanal Endoscopic Total Mesorectal Excision Combined With Single-Port Laparoscopy. Diseases of the Colon and Rectum, 2012, 55, 996-1001.	1.3	90
33	Early and Long-term Oncological Outcomes After Laparoscopic Resection for Colorectal Liver Metastases. Annals of Surgery, 2015, 262, 794-802.	4.2	88
34	Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. Nature Cell Biology, 2018, 20, 296-306.	10.3	88
35	Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases in Patients at High Risk of Hepatic Recurrence. Annals of Surgery, 2013, 257, 114-120.	4.2	76
36	The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surgery, 2021, 156, e206363.	4.3	74

#	Article	IF	CITATIONS
37	Bevacizumab Doubles the Early Postoperative Complication Rate after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis of Colorectal Origin. Annals of Surgical Oncology, 2014, 21, 1792-1800.	1.5	70
38	Prognostic Similarities and Differences in Optimally Resected Liver Metastases and Peritoneal Metastases From Colorectal Cancers. Annals of Surgery, 2015, 261, 157-163.	4.2	68
39	Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). International Journal of Hyperthermia, 2017, 33, 520-527.	2.5	68
40	Self-Expanding Covered Metallic Stent as a Bridge to Surgery in Esophageal Cancer: Impact on Oncologic Outcomes. Journal of the American College of Surgeons, 2015, 220, 287-296.	0.5	65
41	How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Annals of Surgical Oncology, 2019, 26, 109-117.	1.5	64
42	Hepatic Malignancies: Percutaneous Radiofrequency Ablation during Percutaneous Portal or Hepatic Vein Occlusion. Radiology, 2008, 248, 1056-1066.	7.3	63
43	Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. Annals of Surgical Oncology, 2016, 23, 3891-3898.	1.5	63
44	Percutaneous Femoral Implantation of an Arterial Port Catheter for Intraarterial Chemotherapy: Feasibility and Predictive Factors of Long-term Functionality. Journal of Vascular and Interventional Radiology, 2010, 21, 1681-1688.	0.5	62
45	Two-Stage Hepatectomy Versus 1-Stage Resection Combined With Radiofrequency for Bilobar Colorectal Metastases. Annals of Surgery, 2014, 260, 822-828.	4.2	62
46	Role of neoadjuvant treatment in clinical T2NOMO oesophageal cancer: results from a retrospective multi-center European study. European Journal of Cancer, 2016, 56, 59-68.	2.8	62
47	Harvesting the middle hepatic vein with a right hepatectomy does not increase the risk for the donor. Liver Transplantation, 2004, 10, 71-76.	2.4	61
48	Neuroendocrine carcinomas: Optimal surgery of peritoneal metastases (and associated) Tj ETQq0 0 0 rgBT /Overl	ock 10 Tf	50,302 Td (i
49	ls signet-ring cell carcinoma a specific entity among gastric cancers?. Gastric Cancer, 2016, 19, 1027-1040.	5.3	60
50	Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterologie Clinique Et Biologique, 2007, 31, 784-788.	0.9	59
51	Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-) Tj $ETQq1\ 1\ 0.784$	3 1. 6 rgBT ,	/Osserlock 10
52	Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. European Journal of Surgical Oncology, 2021, 47, 36-59.	1.0	57
53	Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Digestive and Liver Disease, 2017, 49, 831-840.	0.9	53
54	A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases. Annals of Surgical Oncology, 2014, 21, 2052-2058.	1.5	52

#	Article	IF	CITATIONS
55	Leukocytosis and neutrophilia predicts outcome in anal cancer. Radiotherapy and Oncology, 2017, 122, 137-145.	0.6	50
56	Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget, 2015, 6, 20840-20850.	1.8	50
57	Complete Radiological Response of Colorectal Liver Metastases after Chemotherapy: What Can We Expect?. Digestive Surgery, 2011, 28, 114-120.	1.2	49
58	Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: a propensity score matching analysis. Hpb, 2016, 18, 781-790.	0.3	48
59	<scp>ROCK</scp> 2 inhibition triggers the collective invasion of colorectal adenocarcinomas. EMBO Journal, 2019, 38, e99299.	7.8	48
60	Nosocomial infection with SARS-Cov-2Âwithin Departments of Digestive Surgery. Journal of Visceral Surgery, 2020, 157, S13-S18.	0.8	47
61	Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. Annals of Surgical Oncology, 2016, 23, 2315-2322.	1.5	46
62	Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer. British Journal of Cancer, 2013, 109, 1013-1022.	6.4	45
63	Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study. European Journal of Endocrinology, 2015, 172, 309-319.	3.7	44
64	Laparoscopic Compared to Open Repeat Hepatectomy for Colorectal Liver Metastases: a Multiâ€institutional Propensityâ€Matched Analysis of Short―and Longâ€Term Outcomes. World Journal of Surgery, 2017, 41, 3189-3198.	1.6	43
65	Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer, 2014, 14, 148.	2.6	42
66	Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study. Annals of Surgical Oncology, 2016, 23, 863-869.	1.5	42
67	The role of image-guided therapy in the management of colorectal cancer metastatic disease. European Journal of Cancer, 2017, 75, 231-242.	2.8	40
68	Intra-Arterial Hepatic Chemotherapy: A Comparison of Percutaneous Versus Surgical Implantation of Port-Catheters. CardioVascular and Interventional Radiology, 2011, 34, 973-979.	2.0	39
69	Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases. Indian Journal of Surgical Oncology, 2016, 7, 225-229.	0.7	39
70	Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. Annals of Surgical Oncology, 2018, 25, 3271-3279.	1.5	38
71	Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Surgical Oncology, 2019, 29, 78-83.	1.6	38
72	The Second Procedure Combining Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy for Isolated Peritoneal Recurrence: Postoperative Course and Long-Term Outcome. Annals of Surgical Oncology, 2009, 16, 2744-2751.	1.5	37

#	Article	IF	Citations
73	Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab. Cancer Research, 2013, 73, 4663-4673.	0.9	36
74	Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget, 2017, 8, 11579-11588.	1.8	36
75	Presentation and prognosis of local recurrence after total mesorectal excision. Colorectal Disease, 2009, 11, 60-66.	1.4	35
76	Current Status and Future Directions in the Treatment of Peritoneal Dissemination from Colorectal Carcinoma. Surgical Oncology Clinics of North America, 2012, 21, 611-623.	1. 5	35
77	Comparison of Complete Pathologic Response and Hepatic Injuries Between Hepatic Arterial Infusion and Systemic Administration of Oxaliplatin in Patients with Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 1925-1932.	1.5	35
78	Predictive Factors of Postoperative Mortality After Junctional and Gastric Adenocarcinoma Resection. JAMA Surgery, 2013, 148, 624.	4.3	33
79	Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases. Liver Cancer, 2017, 6, 72-79.	7.7	32
80	Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design. Pleura and Peritoneum, 2018, 3, 20180120.	1.2	31
81	Oncologic and Functional Results After Abdominoperineal Resection Plus Pseudocontinent Perineal Colostomy for Epidermoid Carcinoma of the Anus. Diseases of the Colon and Rectum, 2009, 52, 958-963.	1.3	30
82	Patients Operated On for Initially Unresectable Colorectal Liver Metastases With Missing Metastases Experience a Favorable Long-Term Outcome. Annals of Surgery, 2011, 254, 114-118.	4.2	30
83	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. Annals of Surgical Oncology, 2018, 25, 1184-1192.	1.5	30
84	Strategies for Preventing Pseudomyxoma Peritonei After Resection of a Mucinous Neoplasm of the Appendix. Anticancer Research, 2015, 35, 4943-7.	1.1	30
85	Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE. Annals of Surgical Oncology, 2018, 25, 1668-1675.	1.5	29
86	HIPEC for Peritoneal Carcinomatosis: Does an Associated Urologic Procedure Increase Morbidity?. Annals of Surgical Oncology, 2012, 19, 104-109.	1.5	27
87	Margin Status is Still an Important Prognostic Factor in Hepatectomies for Colorectal Liver Metastases: A Propensity Score Matching Analysis. World Journal of Surgery, 2018, 42, 892-901.	1.6	27
88	Laparoscopic single port pseudo-continent perineal colostomy. Journal of Visceral Surgery, 2016, 153, 45-53.	0.8	26
89	Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. Annals of Surgical Oncology, 2018, 25, 179-187.	1.5	26
90	Management of colorectal peritoneal metastases: Expert opinion. Journal of Visceral Surgery, 2019, 156, 377-379.	0.8	26

#	Article	IF	CITATIONS
91	The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). European Journal of Surgical Oncology, 2021, 47, 2888-2892.	1.0	26
92	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly: A Case-Controlled, Multicenter Study. Annals of Surgical Oncology, 2016, 23, 737-745.	1.5	25
93	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. Annals of Surgical Oncology, 2017, 24, 3640-3646.	1.5	25
94	Resection of rectal cancer via an abdominal single-port access: short-term results and comparison with standard laparoscopy. Diseases of the Colon and Rectum, 2013, 56, 1203-10.	1.3	25
95	Hiatal hernia after oesophagectomy: a large European survey. European Journal of Cardio-thoracic Surgery, 2019, 55, 1104-1112.	1.4	24
96	Elective surgery for tumours of the splenic flexure: a French inter-group (AFC, SFCD, FRENCH,) Tj ETQq0 0 0 rgBT	/Qverlock	10 Tf 50 54
97	Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?. Journal of Visceral Surgery, 2016, 153, 101-107.	0.8	23
98	Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. Gastroenterologie Clinique Et Biologique, 2007, 31, 281-285.	0.9	22
99	Incidence and Risk Factors Related to Symptomatic Venous Thromboembolic Events After Esophagectomy for Cancer. Annals of Thoracic Surgery, 2016, 102, 979-984.	1.3	22
100	Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer?. International Journal of Hyperthermia, 2017, 33, 505-510.	2.5	22
101	Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter internationalÂstudy. European Journal of Surgical Oncology, 2018, 44, 1786-1792.	1.0	22
102	Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973). BMC Cancer, 2018, 18, 787.	2.6	22
103	Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension. World Journal of Surgery, 2015, 39, 1974-1980.	1.6	20
104	Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian Journal of Surgical Oncology, 2016, 7, 177-187.	0.7	20
105	Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?. European Journal of Cancer, 2018, 100, 94-103.	2.8	20
106	Liver, lung and peritoneal metastases in colorectal cancers: Is the patient still curable? What should the radiologist know. Diagnostic and Interventional Imaging, 2014, 95, 513-523.	3.2	19
107	Interventional oncology for liver and lung metastases from colorectal cancer: The current state of the art. Diagnostic and Interventional Imaging, 2015, 96, 647-654.	3.2	19
108	Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?. Annals of Surgical Oncology, 2016, 23, 1618-1624.	1.5	19

#	Article	IF	CITATIONS
109	Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC. International Journal of Pharmaceutics, 2017, 531, 143-152.	5.2	19
110	Major Hepatectomy for Colorectal Liver Metastases in Patients Aged Over 80: A Propensity Score Matching Analysis. Digestive Surgery, 2018, 35, 333-341.	1.2	19
111	Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry. Annals of Surgical Oncology, 2019, 26, 852-860.	1.5	19
112	Endoscopic internal drainage and low negative-pressure endoscopic vacuum therapy for anastomotic leaks after oncologic upper gastrointestinal surgery. Endoscopy, 2021, , .	1.8	18
113	The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Supportive Care in Cancer, 2009, 17, 1255-1261.	2.2	17
114	Peritoneal Metastases from Colorectal Cancer. Surgical Oncology Clinics of North America, 2018, 27, 563-583.	1.5	17
115	Adenocarcinoma of the oesophagogastric junction Siewert II: An oesophageal cancer better cured with total gastrectomy. European Journal of Surgical Oncology, 2019, 45, 2473-2481.	1.0	17
116	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. European Journal of Surgical Oncology, 2021, 47, 4-10.	1.0	16
117	Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). European Journal of Surgical Oncology, 2021, 47, 89-100.	1.0	16
118	A common hepatic artery passing in front of the portal vein. Surgical and Radiologic Anatomy, 2006, 28, 202-205.	1.2	15
119	Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. Hormones and Cancer, 2017, 8, 330-337.	4.9	15
120	Postoperative Infectious Complications Impact Long-Term Survival in Patients Who Underwent Hepatectomies for Colorectal Liver Metastases: a Propensity Score Matching Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 2045-2054.	1.7	15
121	Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups. Journal of Visceral Surgery, 2020, 157, S25-S31.	0.8	15
122	Development and internal validation of a diagnostic score for gastric linitis plastica. Gastric Cancer, 2020, 23, 639-647.	5.3	15
123	Options and outcome for reconstruction after extended left hemicolectomy. Colorectal Disease, 2013, 15, 747-754.	1.4	14
124	Ovarian Metastasis Is Associated with Retroperitoneal Lymph Node Relapses in Women Treated for Colorectal Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2013, 20, 491-496.	1.5	14
125	Outcomes of Rehepatectomy for Colorectal Liver Metastases: A Contemporary Multi-Institutional Analysis from the French Surgical Association Database. Annals of Surgical Oncology, 2016, 23, 894-903.	1.5	14
126	Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded). Bulletin Du Cancer, 2017, 104, 402-406.	1.6	14

#	Article	IF	Citations
127	Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Annals of Surgical Oncology, 2018, 25, 1094-1100.	1.5	14
128	Preoperative Portal Vein Embolization Tailored to Prepare the Liver for Complex Resections: Initial Experience. CardioVascular and Interventional Radiology, 2010, 33, 976-982.	2.0	13
129	Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. Fundamental and Clinical Pharmacology, 2013, 27, 434-442.	1.9	13
130	Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. European Journal of Surgical Oncology, 2019, 45, 371-375.	1.0	13
131	Comparison Between the Minimum Margin Defined on Preoperative Imaging and the Final Surgical Margin After Hepatectomy for Cancer: How to Manage It?. Annals of Surgical Oncology, 2008, 15, 777-781.	1.5	12
132	Impact of perineal pseudocontinent colostomy on perineal wound healing after abdominoperineal resection. Journal of Surgical Oncology, 2012, 105, 628-631.	1.7	12
133	Interventional revisions of malfunctions affecting surgically implanted port-catheters for hepatic artery infusion. Surgical Oncology, 2013, 22, 48-54.	1.6	12
134	Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer. Future Oncology, 2017, 13, 907-918.	2.4	12
135	Pancreatic cancer: From pathogenesis to cure. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 997-1014.	2.4	11
136	Lymph road mapping obtained via blue sentinel node detection to avoid middle colic artery resection for highly selected colon cancer cases: proof of a concept?. Techniques in Coloproctology, 2010, 14, 237-240.	1.8	11
137	A preâ€operative nomogram for decision making in oncological surgical emergencies. Journal of Surgical Oncology, 2014, 109, 721-725.	1.7	11
138	Orthotopic Animal Model of Pseudomyxoma Peritonei. American Journal of Pathology, 2014, 184, 1920-1929.	3.8	11
139	Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD,) Tj ETQq1	1 0.9 8431	l 41ngBT /Ove
140	Sentinel Lymph Node Sampling and Analysis in Colon Cancer: What Is the Question?. Journal of Clinical Oncology, 2006, 24, 3712-3713.	1.6	10
141	Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate. Journal of Experimental and Clinical Cancer Research, 2011, 30, 92.	8.6	10
142	A New Policy Regarding Ovarian Resection in Young Women Treated for Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2013, 20, 1837-1842.	1.5	10
143	Incidence and prognosis of synchronous colorectal carcinomatosis. Future Oncology, 2013, 9, 541-549.	2.4	9
144	Surgical strategy for low rectal cancers. Journal of Visceral Surgery, 2015, 152, 23-31.	0.8	9

#	Article	IF	Citations
145	Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypNO Rectal Cancer. Annals of Surgical Oncology, 2017, 24, 1304-1311.	1.5	9
146	Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study – SULTAN UCGI 30/PRODIGE 53 (NCTO3164655)- study protocol. BMC Cancer, 2020, 20, 74.	2.6	9
147	Postoperative peritonitis without an underlying digestive fistula after complete cytoreductive surgery plus HIPEC. Saudi Journal of Gastroenterology, 2013, 19, 271.	1.1	8
148	The Landmark Series: Surgical Treatment of Colorectal Cancer Peritoneal Metastases. Annals of Surgical Oncology, 2021, 28, 4140-4150.	1.5	7
149	Abdominal surgical emergencies in patients with advanced cancer. Journal of Visceral Surgery, 2015, 152, S91-S96.	0.8	6
150	Strategies for Managing Intraoperative Discovery of Limited Colorectal Peritoneal Metastases. Annals of Surgical Oncology, 2019, 26, 1437-1444.	1.5	6
151	Multicystic peritoneal mesothelioma treated with cytoreductive surgery followed or not by hyperthermic intraperitoneal chemotherapy: results from a large multicentric cohort. International Journal of Hyperthermia, 2021, 38, 805-814.	2.5	6
152	Incidence and prognosis of synchronous colorectal carcinomatosis: evolution since 1985?. Future Oncology, 2011, 7, 1265-1268.	2.4	5
153	Are we reproducible in measurement of NET liver metastasis?. Digestive and Liver Disease, 2017, 49, 1121-1127.	0.9	5
154	Ovarian and peritoneal psammocarcinoma: Results of a multicenter study on 25 patients. European Journal of Surgical Oncology, 2020, 46, 862-867.	1.0	5
155	Half of Postoperative Deaths After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Could be Preventable. Annals of Surgery, 2021, 274, 797-804.	4.2	5
156	Model predicting the ypNO status after good response to chemoradiotherapy in rectal cancer. American Journal of Surgery, 2018, 216, 438-443.	1.8	4
157	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101681.	1.5	4
158	Peritoneal Carcinomatosis of Colorectal Origin: Recent Advances and Future Evolution Toward a Curative Treatment., 2007, 169, 115-122.		4
159	Treatment of colorectal peritoneal metastases requires multidisciplinary efforts. Lancet Oncology, The, 2016, 17, 1630-1631.	10.7	3
160	Single-port endoscopic mesocolic and mesorectal excision using an extraperitoneal approach. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 469-475.	2.4	3
161	Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study. European Journal of Surgical Oncology, 2018, 44, 799-804.	1.0	3
162	Surgical management of gastric adenocarcinoma. Official expert recommendations delivered under the aegis of the French Association of Surgery (AFC). Journal of Visceral Surgery, 2020, 157, 117-126.	0.8	3

#	Article	IF	CITATIONS
163	Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 599-608.	2.5	3
164	What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatinâ€Based Chemotherapy? A Multidisciplinary Interâ€Group Survey. World Journal of Surgery, 2021, 45, 822-830.	1.6	3
165	H-Pouch: New Isoperistaltic Colonic Pouch For Coloanal Anastomosis After Rectal Resection For Cancer. A Pilot Study. Diseases of the Colon and Rectum, 2004, 47, 1740-1744.	1.3	2
166	Strategies for Resection Using Portal Vein Embolization: Metastatic Liver Cancer. Seminars in Interventional Radiology, 2008, 25, 123-131.	0.8	2
167	Surgical approach for hepatectomy. Journal of Visceral Surgery, 2011, 148, e422-e426.	0.8	2
168	Role of aggressive surgery for peritoneal metastases. European Journal of Cancer, Supplement, 2013, 11, 268-269.	2.2	1
169	Reply to Letter. Annals of Surgery, 2014, 259, e52.	4.2	1
170	Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori, 2018, 104, NP38-NP41.	1.1	1
171	A prolonged follow-up provides new insights into locally advanced pancreatic cancer treatment. Gastroenterologie Clinique Et Biologique, 2008, 32, 649-652.	0.9	0
172	Cancer colorectal métastatique : repousser les limites de la résécabilité. Journal De Chirurgie Viscérale, 2011, 148, S17-S23.	0.0	0
173	Colectomie subtotale par laparoscopie à trocart unique pour polypose adénomateuse familiale. Journal De Chirurgie Viscérale, 2012, 149, 127-134.	0.0	0
174	Résection antérieure du rectum avec exérèse totale du mésorectum par cœlioscopie single port. Journal De Chirurgie Viscérale, 2013, 150, 208-212.	0.0	0
175	Caractérisation des tumeurs neuroendocrines digestives ou thoraciques. Oncologie, 2013, 15, 505-509.	0.7	O
176	Greffon autologue péritonéo-fascialÂ: technique de reconstruction vasculaire. Journal De Chirurgie Viscérale, 2014, 151, 475-478.	0.0	0
177	Adjuvant HIPEC in Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 313-320.	0.5	O
178	La perfusion isolée de pelvis dans les récidives pelviennes non opérables en zone irradiéesÂ: résultats essai en cours. Journal De Chirurgie Viscérale, 2014, 151, S11-S16.	et 0.0	0
179	Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?. Current Colorectal Cancer Reports, 2015, 11, 78-83.	0.5	O
180	Assistance nutritionnelle parentérale et entérale (hors immunonutrition). Journal De Chirurgie Viscérale, 2015, 152, 8-14.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Colostomie pÃ@rinÃ@ale pseudocontinente par cÅ"lioscopie single port. Journal De Chirurgie ViscÃ@rale, 2016, 153, 44-52.	0.0	0
182	Peritoneal Metastases., 2017,, 333-345.		0
183	ASO Author Reflections: What is the Best Therapeutic Strategy for Patients with Limited Synchronous Peritoneal Metastases of Colorectal Cancer?. Annals of Surgical Oncology, 2019, 26, 818-818.	1.5	O
184	Multiple colic intussusceptions. Clinical Case Reports (discontinued), 2019, 7, 1265-1266.	0.5	0
185	Results from the PROPHYLOCHIP-PRODIGE 15 trial – Authors' reply. Lancet Oncology, The, 2020, 21, e498.	10.7	0
186	Influence of bevacizumab on early postoperative complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin Journal of Clinical Oncology, 2012, 30, 601-601.	1.6	0